Data Sheet 2_An anoikis-related gene signature predicts prognosis and immunotherapy respon

Data Sheet 2 from a study by Yan Chen, last updated in May 2026, presents a six-gene prognostic signature based on anoikis-related genes (ARGs) for triple-negative breast cancer (TNBC). The signature stratifies patients into high- and low-risk groups and is associated with the immunogenomic landscape and predicted response to targeted therapy and immunotherapy. The study identifies CCAR2 as a key gene influencing metastasis, stemness, and immune evasion.

Use Cases

• Developing prognostic models for TNBC patient survival based on a six-gene anoikis-related signature.
• Investigating the association between gene expression and the immunogenomic landscape in TNBC.
• Predicting patient response to targeted therapy and immunotherapy using the gene signature.
• Studying the role of the CCAR2 gene in anoikis resistance, cell migration, invasion, and stemness.

Strengths

• The prognostic signature is based on a specific set of six anoikis-related genes.
• Validation included RT-qPCR, immunohistochemistry, and in vitro functional experiments for the key gene CCAR2.
• The associated clinical nomogram is described as achieving good calibration and strong discriminatory accuracy.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 684.9 KB DOCX file, suggesting a limited scope of contained data.

Provenance

Source

Yan Chen, via figshare.

Collection Method

Cox regression, random survival forest analysis, and bioinformatics analyses performed on anoikis-related genes.

Freshness

Last updated 2026-05-20 05:47:36; freshness should be verified.